Announcements Trials
Browse Landscape

Status

Completed 28Terminated 13Recruiting 12Active not recruiting 5Unknown 1Suspended 1Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Multiple Myeloma 15Melanoma 14Carcinoma, Non-Small-Cell Lung 13Recurrence 12Neoplasms 12Leukemia, Myeloid, Acute 9Glioblastoma 8Prostatic Neoplasms 6Lung Neoplasms 6Breast Neoplasms 6Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Sarcoma 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Gastrointestinal Stromal Tumors 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia 2

Interventions

Miransertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT03317366 2021-08-06

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

No longer available

Congenital Abnormalities, Growth Disorders, Hereditary Sensory and Autonomic Neuropathies, Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡